Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

Sander Herfst; Eefje Schrauwen; Miranda de Graaf; Geert Amerongen; BG van den Hoogen; Rik de Swart; Ab Osterhaus; Ron Fouchier

doi:10.1016/j.vaccine.2008.05.052

Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

Sander Herfst, Eefje Schrauwen, Miranda de Graaf, Geert Amerongen, BG van den Hoogen, Rik de Swart, Ab Osterhaus, Ron Fouchier

Virology

Research output: Contribution to journal › Article › Academic › peer-review

42 Citations (Scopus)

Abstract

Human metapneumovirus (HMPV) is an important cause of acute respiratory tract disease for which the development of vaccine candidates is warranted. We have previously described the generation of an iscom matrix-adjuvanted HMPV fusion protein subunit vaccine (Fsol) and a live-attenuated vaccine (HMPVM11). Here, we evaluate the immunogenicity and efficacy of these vaccines in cynomolgus macaques. Immunization with Fsol induced HMPV F-specific antibody responses, virus neutralizing antibody titers, and cellular immune responses, but the induced humoral immune response waned rapidly over time. HMPVM11 was strongly attenuated and displayed limited immunogenicity, although immunization with this virus rimed for a good secondary HMPV-specific lymphoproliferative response after challenge infection. The duration of virus shedding in HMPVM11-immunized animals was reduced compared to sham-immunized animals. Both vaccines induced HMPV-specific immune responses, but the rapid waning of immunity is a challenging obstacle for vaccine development. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	4224-4230
Number of pages	7
Journal	Vaccine
Volume	26
Issue number	33
DOIs	https://doi.org/10.1016/j.vaccine.2008.05.052
Publication status	Published - 2008

Research programs

EMC MM-04-27-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.05.052

http://hdl.handle.net/1765/29520

Cite this

@article{92884faf5c7d4a349e99fe8774fbcf5f,

title = "Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques",

abstract = "Human metapneumovirus (HMPV) is an important cause of acute respiratory tract disease for which the development of vaccine candidates is warranted. We have previously described the generation of an iscom matrix-adjuvanted HMPV fusion protein subunit vaccine (Fsol) and a live-attenuated vaccine (HMPVM11). Here, we evaluate the immunogenicity and efficacy of these vaccines in cynomolgus macaques. Immunization with Fsol induced HMPV F-specific antibody responses, virus neutralizing antibody titers, and cellular immune responses, but the induced humoral immune response waned rapidly over time. HMPVM11 was strongly attenuated and displayed limited immunogenicity, although immunization with this virus rimed for a good secondary HMPV-specific lymphoproliferative response after challenge infection. The duration of virus shedding in HMPVM11-immunized animals was reduced compared to sham-immunized animals. Both vaccines induced HMPV-specific immune responses, but the rapid waning of immunity is a challenging obstacle for vaccine development. (C) 2008 Elsevier Ltd. All rights reserved.",

author = "Sander Herfst and Eefje Schrauwen and {de Graaf}, Miranda and Geert Amerongen and {van den Hoogen}, BG and {de Swart}, Rik and Ab Osterhaus and Ron Fouchier",

year = "2008",

doi = "10.1016/j.vaccine.2008.05.052",

language = "Undefined/Unknown",

volume = "26",

pages = "4224--4230",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "33",

}

TY - JOUR

T1 - Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

AU - Herfst, Sander

AU - Schrauwen, Eefje

AU - de Graaf, Miranda

AU - Amerongen, Geert

AU - van den Hoogen, BG

AU - de Swart, Rik

AU - Osterhaus, Ab

AU - Fouchier, Ron

PY - 2008

Y1 - 2008

N2 - Human metapneumovirus (HMPV) is an important cause of acute respiratory tract disease for which the development of vaccine candidates is warranted. We have previously described the generation of an iscom matrix-adjuvanted HMPV fusion protein subunit vaccine (Fsol) and a live-attenuated vaccine (HMPVM11). Here, we evaluate the immunogenicity and efficacy of these vaccines in cynomolgus macaques. Immunization with Fsol induced HMPV F-specific antibody responses, virus neutralizing antibody titers, and cellular immune responses, but the induced humoral immune response waned rapidly over time. HMPVM11 was strongly attenuated and displayed limited immunogenicity, although immunization with this virus rimed for a good secondary HMPV-specific lymphoproliferative response after challenge infection. The duration of virus shedding in HMPVM11-immunized animals was reduced compared to sham-immunized animals. Both vaccines induced HMPV-specific immune responses, but the rapid waning of immunity is a challenging obstacle for vaccine development. (C) 2008 Elsevier Ltd. All rights reserved.

AB - Human metapneumovirus (HMPV) is an important cause of acute respiratory tract disease for which the development of vaccine candidates is warranted. We have previously described the generation of an iscom matrix-adjuvanted HMPV fusion protein subunit vaccine (Fsol) and a live-attenuated vaccine (HMPVM11). Here, we evaluate the immunogenicity and efficacy of these vaccines in cynomolgus macaques. Immunization with Fsol induced HMPV F-specific antibody responses, virus neutralizing antibody titers, and cellular immune responses, but the induced humoral immune response waned rapidly over time. HMPVM11 was strongly attenuated and displayed limited immunogenicity, although immunization with this virus rimed for a good secondary HMPV-specific lymphoproliferative response after challenge infection. The duration of virus shedding in HMPVM11-immunized animals was reduced compared to sham-immunized animals. Both vaccines induced HMPV-specific immune responses, but the rapid waning of immunity is a challenging obstacle for vaccine development. (C) 2008 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2008.05.052

DO - 10.1016/j.vaccine.2008.05.052

M3 - Article

C2 - 18585830

SN - 0264-410X

VL - 26

SP - 4224

EP - 4230

JO - Vaccine

JF - Vaccine

IS - 33

ER -